ABVC BioPharma, Inc. has received a $150,000 licensing payment from AiBtl BioPharma Inc., representing a crucial advancement in bringing its late-stage drug candidates ABV-1504 for Major Depressive Disorder and ABV-1505 for Attention Deficit Hyperactivity Disorder to market. This transaction forms part of a comprehensive licensing agreement that has elevated ABVC's total licensing revenue to $846,000 through various strategic partnerships. The company's licensing-first approach aims to generate non-dilutive revenue by collaborating with partners, as demonstrated through agreements with AiBtl, ForSeeCon Eye Corporation, and OncoX BioPharma, Inc. These partnerships deliver immediate financial gains while establishing a foundation for sustained growth via milestone payments, royalties, and equity positions in partner entities.
Dr. Uttam Patil, ABVC Chief Executive Officer, highlighted the effectiveness of this strategy in enhancing shareholder value and meeting the worldwide demand for alternative central nervous system therapies. The increasing need for such treatments is reinforced by recent reports documenting drug shortages impacting hundreds of thousands of patients globally. ABVC's advancements in botanical drug development, especially through its collaboration with AiBtl, present a viable alternative for patients pursuing legal and effective treatments for CNS disorders. The company's asset-light business model and emphasis on licensing late-stage clinical products to commercial partners reflect its dedication to innovation and international expansion within the biopharmaceutical sector. Additional information about ABVC BioPharma can be found at https://www.abvcbiopharma.com.
